[Pseudomonas aeruginosa infection].
Oishi
Kazunori
K
Department of Internal Medicine, Institute of Tropical Medicine, Nagasaki University.
D042462:4-Quinolones; D000890:Anti-Infective Agents / Q000627:therapeutic use; D016470:Bacteremia; D018441:Biofilms; D015780:Carbapenems / Q000627:therapeutic use; D002511:Cephalosporins / Q000627:therapeutic use; D010861:Fimbriae, Bacterial; D005407:Flagella; D006801:Humans; D016867:Immunocompromised Host; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D011379:Prognosis; D011552:Pseudomonas Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000235:genetics / Q000472:pathogenicity*; D012141:Respiratory Tract Infections; D018805:Sepsis; D015534:Trans-Activators; D014552:Urinary Tract Infections
D042462:4-Quinolones; D000890:Anti-Infective Agents; D015780:Carbapenems; D002511:Cephalosporins; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D015534:Trans-Activators